A phase I/II trial of cord blood (CB)-derived HLA-mismatched CD19-CAR-NK cells with an escalating dose was conducted in relapsed or refractory chronic lymphocytic leukemia (CLL) or non-Hodgkin’s lymphoma patients (NCT03056339) [55]. Here, CD19 is linked to B-cell chronic lymphocytic leukemia.